Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

  • End date
    Jun 1, 2023
  • participants needed
  • sponsor
    University of Alabama at Birmingham
Updated on 20 June 2022
positron emission tomography
idiopathic pulmonary fibrosis
forced vital capacity


The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose ([18F] FDG) and fluorine-18 Displacement Per Atom ([18F]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.

Condition Idiopathic Pulmonary Fibrosis
Treatment PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
Clinical Study IdentifierNCT04362644
SponsorUniversity of Alabama at Birmingham
Last Modified on20 June 2022


Yes No Not Sure

Inclusion Criteria

Age between 40-85 years old
A diagnosis of IPF that fulfills American Thoracic Society (ATS) / European Respiratory Society (ERS) 2018 consensus criteria within 5 years
Ability and willingness to give informed consent and adhere to study requirements
Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) >0.70
High or mixed affinity binder for TSPO ligands based on genotyping for single-nucleotide polymorphism (SNP)rs6971

Exclusion Criteria

Acute exacerbation of IPF within <30 days
Diagnosis of Diabetes Mellitus (Type 1 or Type 2)
Diagnoses of current infection by clinical or microbial assessments
Treatment for >14 days within the preceding month with >20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant
Subjects with prior radiation therapy to the thorax
Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration
Severe cardiovascular disease, defined as any of the following within the preceding 12 weeks: acute myocardial infarction or unstable angina, a coronary revascularization procedure, or stroke
Subjects with known liver disease
Diagnosis of any active cancer with the exception of basal cell carcinoma of skin
Low affinity binder for TSPO ligands based on genotyping for SNP rs6971
Active cigarette smoking or vaping
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note